Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Structure Therapeutics (NASDAQ:GPCR) and maintained a price target of $65.
September 23, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Structure Therapeutics, maintaining a $65 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and a maintained price target of $65 by Cantor Fitzgerald suggests a positive outlook for Structure Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100